Hormone Health · Peptide Guide
One of the most common misconceptions in hormone optimisation is that peptides and hormone therapy are competing alternatives, that you choose one or the other. In clinical practice, they…
Understanding why requires understanding that the body has more than one hormone axis that declines with age. TRT or HRT addresses the sex hormone axis, testosterone or estrogen. But there is a second system, the growth hormone and IGF-1 axis, that also declines significantly with age and produces a distinct set of symptoms and consequences. GH secretagogue peptides address that second axis. The two therapies are not alternatives; they operate in parallel lanes.
The key insight that makes peptide-hormone combination therapy intelligible is that aging produces parallel hormonal declines along two distinct axes, and TRT or HRT addresses only one of them.
Sex Hormone Axis, What TRT / HRT Addresses
Hormones involved
Testosterone (men, and in smaller amounts in women), estrogen (primarily estradiol), progesterone, DHEA
Primary effects managed
Rate of decline
Testosterone ~1% per year in men after 40. Estrogen drops sharply at menopause. Progesterone often declines first in perimenopause.
GH/IGF-1 Axis, What Peptides Address
Hormones involved
Growth hormone (GH), insulin-like growth factor 1 (IGF-1), GHRH (stimulates GH from pituitary), ghrelin
Primary effects managed
Rate of decline
GH secretion declines ~14% per decade after peak in young adulthood. By age 60, GH output may be 50–70% of peak. This “somatopause” is distinct from, and parallel to, gonadal hormone decline.
When a man starts TRT, his testosterone levels improve and he typically sees gains in libido, mood, energy, and some body composition improvements. What TRT does not address: the parallel GH/IGF-1 decline that reduces recovery capacity, impairs sleep architecture, allows visceral fat to accumulate despite normal testosterone, and contributes to the tissue repair deficits that come with aging.
This is why clinicians often find that men on TRT reach a plateau in body composition improvement, and why the addition of GH secretagogues can produce additional gains that testosterone alone cannot explain. The two axes are complementary, not redundant.
Body Composition, Complementary Mechanisms
Testosterone drives muscle protein synthesis via androgen receptor signalling, activates satellite cells for muscle repair, and increases myonuclear density. GH/IGF-1 increases amino acid uptake into muscle cells, stimulates intracellular anabolic signalling (mTOR), and reduces protein breakdown. These are additive pathways, activating both simultaneously produces greater lean mass benefit than either alone. Clinical experience consistently confirms that men on TRT + GH secretagogues achieve better body composition outcomes than TRT alone.[1]Sleep and Recovery, Different but Convergent
Testosterone contributes to recovery through anabolic pathways and improved mood/motivation. GH secretagogues work through a different mechanism: amplifying the natural nocturnal GH pulse during slow-wave sleep, improving sleep architecture directly. Better slow-wave sleep increases GH release, which supports tissue repair during sleep. This is where the combined effect on recovery is most pronounced: better sleep quality enables more GH release, which accelerates tissue repair, which improves next-day performance and training tolerance.
Fat Metabolism, Visceral Adiposity
Both low testosterone and low GH independently drive visceral fat accumulation, but through different mechanisms. Testosterone deficiency reduces lipolysis and promotes central fat deposition. Low GH/IGF-1 specifically drives visceral adiposity and reduces the metabolic activity of fat cells. TRT addresses the testosterone-driven component; GH peptides (particularly tesamorelin, which has FDA approval for HIV lipodystrophy-related visceral fat) address the GH-axis component. In patients with both deficiencies, addressing one without the other may produce partial results.
Metabolic Health, Insulin Sensitivity
Testosterone improves insulin sensitivity and reduces the risk of type 2 diabetes in hypogonadal men. GH/IGF-1 supports glucose metabolism through different pathways, particularly through IGF-1’s insulin-sensitising effects on skeletal muscle. The combination produces metabolic benefit across both mechanisms, particularly relevant for men with metabolic syndrome or prediabetes who have concurrent sex hormone and GH axis decline.
Bone Density, Dual Pathway Support
Testosterone maintains bone density via androgen receptors, reducing osteoclast activity. GH/IGF-1 promotes bone formation through osteoblast stimulation and is one of the primary drivers of peak bone mass in young adulthood. Combining TRT with GH peptide support may produce additive bone density protection, particularly relevant for men with osteoporosis risk or women entering early menopause.
Collagen and Tissue Repair
Sex hormones have some role in skin collagen maintenance; estrogen in particular supports collagen synthesis in women. But the primary driver of collagen synthesis and tissue repair in adults is the GH/IGF-1 axis, which is why soft tissue injuries often heal poorly in older adults with GH decline. GH peptides like sermorelin and ipamorelin, and separately BPC-157 (which works through growth factor modulation rather than the GH axis), address this dimension specifically. This is not a domain where TRT or HRT produces direct benefits.
Hormone Therapy, Uniquely Addresses
Peptides, Uniquely Address
Scenario 1, Most Common
A man in his 50s on TRT for 18 months has normalised testosterone but continues to struggle with visceral fat, poor sleep, and slower-than-expected recovery from training. His IGF-1 comes back in the low-normal range, suggesting concurrent GH axis decline. The GH deficit is a separate diagnosis from the hypogonadism, both of which are contributing to his presentation.
Typical addition: CJC-1295 + Ipamorelin nightly
Scenario 2, Women’s Health
A woman of 48 is on transdermal estradiol + micronised progesterone for perimenopausal symptoms, with good symptom relief. She wants support for the body composition changes of perimenopause, particularly visceral fat gain and muscle loss, that HRT has not fully addressed. Sermorelin or CJC-1295 + ipamorelin added as a separate GH axis intervention.
Typical addition: Sermorelin nightly, or CJC-1295 + Ipamorelin
Scenario 3, GLP-1 + Hormone Therapy
A man is on semaglutide for obesity-related metabolic syndrome. Significant weight loss is occurring, but he is also losing lean muscle mass, a known concern with GLP-1 medications in the absence of adequate anabolic support. TRT (or confirmed hypogonadism being treated with TRT) is used to maintain the anabolic environment. GH secretagogues may be added to further support lean mass preservation and the recovery capacity needed to maintain training during aggressive weight loss.
Typical combination: GLP-1 + TRT + optional GH secretagogue
Scenario 4, Injury Recovery
A man on a stable TRT protocol sustains a rotator cuff injury. His testosterone is optimised, but soft tissue repair is a GH/peptide domain, not a testosterone domain. BPC-157 is added for its tissue-repair and anti-inflammatory properties. TB-500 may also be added for actin-regulation and angiogenesis support. These are added on top of TRT, not instead of it.
Typical addition: BPC-157 250–500mcg daily (or twice daily), ± TB-500
Scenario 5, Longevity Protocol
A physician designs a comprehensive protocol for a 55-year-old patient: lifestyle optimisation first, then TRT for confirmed hypogonadism, then GH secretagogues for the parallel GH axis decline, then NAD+ precursors and GHK-Cu for cellular repair. Each layer addresses a different system. The sex hormones are the foundation; peptides and supplements build upward.
Layer architecture: Lifestyle → TRT → GH peptides → Cellular repair peptides
1
Establish the sex hormone foundation first. Whether TRT or HRT, sex hormone therapy is initiated and stabilised before GH peptides are added. Trying to optimise both simultaneously makes clinical interpretation more difficult, if a patient has a side effect or inadequate response, it is harder to identify the source.
2
Reassess at 3–4 months. Once testosterone or estrogen levels are stable and symptoms are responding, the clinical picture is clear enough to identify what remains unaddressed. Body composition concerns, poor sleep, slow recovery, or low IGF-1 on repeat testing become the next targets.
3
Assess the GH axis specifically. IGF-1 measurement establishes baseline GH axis status. If low for age, GH peptides have a clear indication. If already normal, the incremental benefit of GH peptides is less certain and the decision is more nuanced.
4
Add GH secretagogues with clear goals. Sleep improvement, body composition, recovery capacity, or visceral fat reduction. The goals should be defined, and outcomes measured over 3–6 months. Body composition (DEXA), sleep quality, and IGF-1 levels are the primary tracking markers.
5
Tissue repair peptides are situational, not foundational. BPC-157, TB-500, and GHK-Cu are added when specific clinical needs arise, injury recovery, inflammatory conditions, skin health. They are not part of the standing protocol unless the specific target indication is ongoing.
The menopausal transition involves not just estrogen and progesterone decline, it also involves accelerated GH axis decline. Women who experience significant body composition changes during perimenopause (visceral fat gain, muscle loss, worsening recovery) are often dealing with both the sex hormone deficit addressed by HRT and the GH axis deficit that HRT does not address.
Sermorelin in particular is commonly used in women as an adjunct to HRT, or as an alternative for women who cannot or choose not to use systemic estrogen. It does not produce the hot flash and vasomotor symptom relief that estrogen provides, those effects are specific to the estrogen receptor pathway. But it can meaningfully support the body composition, sleep quality, energy, and recovery dimensions of the menopausal transition that HRT may not fully address.
Women who are not candidates for systemic HRT (due to cancer history or personal preference) can sometimes benefit significantly from GH secretagogue therapy as a partial alternative, not because it replaces estrogen’s functions, but because it addresses the GH axis decline that runs in parallel.
The Framing That Gets It Right
Peptides and hormone therapy are not competing for the same therapeutic territory. TRT and HRT restore the sex hormone environment that aging depletes. GH secretagogues restore the GH/IGF-1 signalling environment that aging simultaneously depletes by a different mechanism. BPC-157 and GHK-Cu address tissue repair and cellular biology that neither sex hormones nor GH directly address. A comprehensive hormone optimisation protocol, one that actually produces the full set of outcomes patients are seeking, addresses all of these in an ordered, monitored, physician-supervised framework.
Our free quiz helps you think through your goals before speaking with a clinician.